Table 2.
The BP parameters (mm Hg) observed for patients assigned to add-on treatment with eplerenone (50 mg/day) and standard hypertensive treatment before (V1) and after 6 months (V2). All values are reported as median (interquartile range). The statistical comparison of parameters before (V1) and after treatment (V2) were conducted with Wilcoxon test (WLCXN) while the eplerenone versus standard hypertensive treatment comparison was conducted with Mann–Whitney U test (MW-U).
| Add-On Therapy—with Eplerenone | Standard Antihypertensive Therapy | |||
|---|---|---|---|---|
| cSBP | V1 | 150.0 (144.0–155.0) | 148.0 (145.0–155.0) | p > 0.05 |
| V2 | 142.0 (138.0–145.0) | 149 (144.0–153.0) | p < 0.001 | |
| WLCXN | p < 0.001 | p > 0.05 | ||
| cDBP | V1 | 92.0 (89.0–99.0) | 91.0 (90.0–98.0) | p > 0.05 |
| V2 | 90.0 (84.0–93.0) | 91.0 (88.0–98.0) | p < 0.001 | |
| WLCXN | p < 0.001 | p > 0.05 | ||
| SBPd | V1 | 147.7 (141.2–155.2) | 147.6 (142.3–154.3) | p > 0.05 |
| V2 | 140.3 (137.7–147.5) | 146.6 (141.3–152.3) | p < 0.001 | |
| WLCXN | p < 0.001 | p > 0.05 | ||
| DBPd | V1 | 96.5 (90.2–101.0) | 96.4 (92.3–99.8) | p > 0.05 |
| V2 | 90.3 (86.2–94.7) | 95.5 (91.8–99.5) | p < 0.001 | |
| WLCXN | p < 0.001 | p > 0.05 | ||
| MAPd | V1 | 112.8 (109.2–117.6) | 112.9 (110.7–116.6) | p > 0.05 |
| V2 | 107.5 (103.7–110.3) | 112.8 (109.7–116.1) | p < 0.001 | |
| WLCXN | p < 0.001 | p > 0.05 | ||
| SBPn | V1 | 141.0 (132.1–146.8) | 136.7 (132.0–140.3) | p > 0.05 |
| V2 | 125.4 (121.0–131.6) | 136.5 (133.3–140.4) | p < 0.001 | |
| WLCXN | p < 0.001 | p > 0.05 | ||
| DBPn | V1 | 91.2 (86.7–97.8) | 90.1 (85.8–93.2) | p > 0.05 |
| V2 | 84.4 (80.2–89.8) | 90.3 (86.6–92.3) | p < 0.001 | |
| WLCXN | p < 0.001 | p > 0.05 | ||
| MAPn | V1 | 108.3 (103.1–114.6) | 104.5 (102.0–107.6) | p > 0.05 |
| V2 | 98.2 (94.6–103.1) | 104.9 (102.0–107.4) | p < 0.001 | |
| WLCXN | p < 0.001 | p > 0.05 | ||
| SBP-24 | V1 | 142.9 (139.4–151.2) | 143.3 (140.4–150.3) | p > 0.05 |
| V2 | 138.5 (133.3–142.2) | 142.8 (139.4–149.0) | p < 0.001 | |
| WLCXN | p < 0.001 | p > 0.05 | ||
| DBP-24 | V1 | 94.3 (88.8–99.9) | 93.5 (90.8–97.8) | p > 0.05 |
| V2 | 88.7 (82.6–92.5) | 94.0 (91.1–97.8) | p < 0.001 | |
| WLCXN | p < 0.001 | p > 0.05 | ||
| MAP-24 | V1 | 109.9 (106.9–116.6) | 111.0 (109.1–114.3) | p > 0.05 |
| V2 | 104.8 (101.3–108.0) | 111.0 (107.6–113.2) | p < 0.001 | |
| WLCXN | p < 0.001 | p > 0.05 | ||
| NBPF (%) | V1 | 4.6 (2.9–6.2) | 7.7 (6.7–10.0) | p < 0.01 |
| V2 | 8.9 (6.7–10.0) | 7.4 (4.1–10.1) | p > 0.05 | |
| WLCXN | p < 0.001 | p > 0.05 |
cSBP, clinic systolic blood pressure; cDBP, clinic diastolic blood pressure; SBPd, ambulatory day-time systolic blood pressure; DBPd, ambulatory day-time diastolic blood pressure; MAPd, ambulatory day-time mean blood pressure; SBPn, ambulatory night time systolic blood pressure; DBPn, ambulatory night time diastolic blood pressure; MAPn, ambulatory night time mean blood pressure; SBP24, 24 h systolic blood pressure; DBP24, 24-h diastolic blood pressure; MAP24, 24-h mean blood pressure; NBPF, night blood pressure fall.